These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 12206796)
1. Current protocol of a research phase I clinical trial of full-length dystrophin plasmid DNA in Duchenne/Becker muscular dystrophies. Part III. Ethical considerations. Fardeau M Neuromuscul Disord; 2002 Oct; 12 Suppl 1():S52-4. PubMed ID: 12206796 [TBL] [Abstract][Full Text] [Related]
2. Current protocol of a research phase I clinical trial of full-length dystrophin plasmid DNA in Duchenne/Becker muscular dystrophies. Part I: rationale. Thioudellet C; Blot S; Squiban P; Fardeau M; Braun S Neuromuscul Disord; 2002 Oct; 12 Suppl 1():S49-51. PubMed ID: 12206795 [TBL] [Abstract][Full Text] [Related]
3. Current protocol of a research phase I clinical trial of full-length dystrophin plasmid DNA in Duchenne/Becker muscular dystrophies. Part II: clinical protocol. Romero NB; Benveniste O; Payan C; Braun S; Squiban P; Herson S; Fardeau M Neuromuscul Disord; 2002 Oct; 12 Suppl 1():S45-8. PubMed ID: 12206794 [TBL] [Abstract][Full Text] [Related]
4. Myodys, a full-length dystrophin plasmid vector for Duchenne and Becker muscular dystrophy gene therapy. Duan D Curr Opin Mol Ther; 2008 Feb; 10(1):86-94. PubMed ID: 18228186 [TBL] [Abstract][Full Text] [Related]
8. Genomic integration of the full-length dystrophin coding sequence in Duchenne muscular dystrophy induced pluripotent stem cells. Farruggio AP; Bhakta MS; du Bois H; Ma J; P Calos M Biotechnol J; 2017 Apr; 12(4):. PubMed ID: 28139886 [TBL] [Abstract][Full Text] [Related]
9. Intraarterial delivery of naked plasmid DNA expressing full-length mouse dystrophin in the mdx mouse model of duchenne muscular dystrophy. Zhang G; Ludtke JJ; Thioudellet C; Kleinpeter P; Antoniou M; Herweijer H; Braun S; Wolff JA Hum Gene Ther; 2004 Aug; 15(8):770-82. PubMed ID: 15319034 [TBL] [Abstract][Full Text] [Related]
10. Therapeutic strategies for Duchenne and Becker dystrophies. Voisin V; de la Porte S Int Rev Cytol; 2004; 240():1-30. PubMed ID: 15548414 [TBL] [Abstract][Full Text] [Related]
15. Gene transfer studies in animals: what do they really tell us about the prospects for gene therapy in DMD? Wells DJ; Wells KE Neuromuscul Disord; 2002 Oct; 12 Suppl 1():S11-22. PubMed ID: 12206790 [TBL] [Abstract][Full Text] [Related]
16. Exon Skipping Therapy Using Phosphorodiamidate Morpholino Oligomers in the mdx52 Mouse Model of Duchenne Muscular Dystrophy. Miyatake S; Mizobe Y; Takizawa H; Hara Y; Yokota T; Takeda S; Aoki Y Methods Mol Biol; 2018; 1687():123-141. PubMed ID: 29067660 [TBL] [Abstract][Full Text] [Related]
17. Dystrophin and the two related genetic diseases, Duchenne and Becker muscular dystrophies. Le Rumeur E Bosn J Basic Med Sci; 2015 Jul; 15(3):14-20. PubMed ID: 26295289 [TBL] [Abstract][Full Text] [Related]